Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Goldman Sachs Downgrades Apellis Pharmaceuticals to Sell, Lowers Price Target to $18

Author: Benzinga Newsdesk | September 26, 2025 11:51am
Goldman Sachs analyst Salveen Richter downgrades Apellis Pharmaceuticals (NASDAQ: APLS) from Neutral to Sell and lowers the price target from $26 to $18.

Posted In: APLS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist